SVT-18651 is under clinical development by Laboratorios Salvat and currently in Phase II for Dermatitis (Eczema). According to GlobalData, Phase II drugs for Dermatitis (Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SVT-18651’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SVT-18651 overview

SVT-18651 is under development for the treatment of otic eczema. The drug candidate is a new therapeutic entity. It is a topical corticosteroid.

Laboratorios Salvat overview

Laboratorios Salvat (Salvat) is a pharmaceutical company with focus on the development and commercialization of innovative medicines. The company’s products include Urosens, Urosens Fort, Urosens Manosa, Audiovit, Bester Complex, Broken, Cristalmina, Donner, Herpix, Magnesium SVT, Megalevure, Megasmect, Mitigal Calmanta, Nasolina, Nurane, Nurane Retina, Nutira, Nutira forte, Nutira Forte to go, Protransitus, Pruritane, Quirocrom, Relive Ojos Secos, Relive Sicca, Salvacalm, Relive Total Care, Salvacolina, Salvacolina Flas, Salvarina, Tinnitan Duo, Vincicalm garganta, Vincigrip among others. The company has operations with a commercial office in the US and markets its products through a network of distributors across Europe, America, Asia and Africa and the Middle East. Salvat is headquartered in Barcelona, Spain.

For a complete picture of SVT-18651’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.